Sanofi, GlaxoSmithKline hit with a major delay on Covid-19 vaccine program as their first jab flops in older adults
Hours after Pfizer and BioNTech won the backing of an FDA panel for their mRNA vaccine, Sanofi and GSK announced that their closely watched program to develop an adjuvanted vaccine to combat Covid-19 had hit a major setback.
The companies announced early Friday that they were delaying their development program for an adjuvanted recombinant protein-based Covid-19 vaccine after it failed among adults older than 49 in the study.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.